Lsd1 inhibition was shown to promote Pd-l1 expression in a mouse model of 4NQO-induced OSCC, and a combination of SP2509, an Lsd1 inhibitor, and anti-Pd-1/anti-Pd-l1 antibodies additively reduced tumor growth in this in vivo model. Here, KDM1A is linked to neoplasm.